Compare Moderna, Inc. (MRNA) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Prudential PLC — how do they compare? Moderna, Inc. trades at $214.64 (market cap $78.65B), while Prudential PLC trades at $23.86 (market cap $28.84B). The key difference: Moderna, Inc. is far larger — about 2.7× Prudential PLC's market cap, and Prudential PLC pays a 2.33% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Prudential PLC for 119 Days on average.
| MRNA | PUK | |
|---|---|---|
Market Cap | $78.65B | $28.84B |
Volume | 37,373,437 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $203.46 | $33.61 |
52-Week Low | $22.36 | $23.54 |
Typical Hold Time | 59 Days | 119 Days |
Enterprise Value | $74.80B | $28.38B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
PUK trades at $23.54, down 4.31% on the day, with a bearish technical signal from moving averages and oscillators. The company reported strong revenue growth to $27.39B in 2025 and net income of $3.98B, with a net margin of 14.52%. Recent news highlights strategic moves including the sale of its Alexforbes stake and a rebranding of its wealth management unit. Analyst consensus is moderately bullish with 50% buy ratings.
The outlook is mixed: solid fundamentals and growth initiatives support upside, but technical weakness and earnings volatility pose risks. Investment opportunity lies in the attractive valuation (P/E 8.4) and strategic focus, countered by bearish momentum and competitive pressures in insurance markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
